Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Boston Partners

Boston Partners raised its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 81.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,580,519 shares of the medical equipment provider's stock after purchasing an additional 1,602,463 shares during the quarter. Boston Partners owned 1.59% of Hologic worth $257,959,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of HOLX. FMR LLC boosted its position in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock worth $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock valued at $159,911,000 after buying an additional 544,889 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Hologic in the 4th quarter valued at about $27,007,000. Swedbank AB grew its holdings in shares of Hologic by 18.8% during the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider's stock worth $157,788,000 after buying an additional 306,562 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider's stock valued at $110,700,000 after buying an additional 238,222 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Remove Ads

Hologic Stock Up 0.8 %

NASDAQ:HOLX traded up $0.46 during mid-day trading on Friday, hitting $61.47. The stock had a trading volume of 7,416,503 shares, compared to its average volume of 1,750,784. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $13.79 billion, a PE ratio of 19.39, a PEG ratio of 2.14 and a beta of 0.97. The stock has a 50-day simple moving average of $66.06 and a two-hundred day simple moving average of $73.99.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Jefferies Financial Group initiated coverage on Hologic in a report on Tuesday, December 10th. They set a "hold" rating and a $85.00 target price on the stock. Raymond James reiterated an "outperform" rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Finally, BNP Paribas raised Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.